![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, September 22, 2023 4:55:24 PM
Sounds like a job for lenzilumab.
But surely not, right? How could lenz possibly eliminate most of the treatment cost, and also improve the complete response rate for patients, when Humanigen's stock price it teetering on one cent?
Dare I to think that this unrealized potential presents promise almost beyond comprehension? Could share price be transient, yet result in lenzilumab demonstrating results that are robust and durable?
This is just about one of the many active opportunities for lenz. I'm here for the realization of all of lenzilumab's opportunities.
And political power is not a factor for this indication. Nor does Big Pharma regulatory influence come into play. When a product is as good as lenz, it can't be denied for everything, and forever.
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM